Brian M. D’Onofrio

Mar 12, 2024 | jamanetwork.com | Lin Li |Brian M. D’Onofrio |Paul Lichtenstein

ADHD Pharmacotherapy and Mortality in Individuals With ADHD Key PointsQuestion  Is initiation of attention-deficit/hyperactivity disorder (ADHD) medication associated with a reduced mortality risk in individuals with ADHD?

Jan 17, 2024 | jamanetwork.com | Yufeng Chen |Paul Lichtenstein |Brian M. D’Onofrio

Key PointsQuestion  Are potentially traumatic events associated with a subsequent risk of psychiatric disorders independent of familial factors?

Nov 22, 2023 | jamanetwork.com | Miguel Garcia-Argibay |Patrick Quinn |Brian M. D’Onofrio

Key PointsQuestion  Is long-term use of attention-deficit/hyperactivity disorder (ADHD) medication associated with an increased risk of cardiovascular disease (CVD)? Findings  In this case-control study of 278 027 individuals in Sweden aged 6 to 64 years who had an incident ADHD diagnosis or ADHD medication dispensation, longer cumulative duration of ADHD medication use was associated with an increased risk of CVD, particularly hypertension and arterial disease, compared with nonuse.